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AMP-activated protein kinase (AMPK) is a heterotrimeric complexcontaining a, β, and γ subunits involved in maintaining integrityand survival of murine red blood cells. Indeed, Ampk a1-/-, Ampk
β1-/- and Ampk γ1-/-mice develop hemolytic anemia and the plasma mem-
brane of their red blood cells shows elasticity defects. The membrane
composition evolves continuously along erythropoiesis and during red
blood cell maturation; defects due to the absence of Ampk could be ini-
tiated during erythropoiesis. We, therefore, studied the role of AMPK
during human erythropoiesis. Our data show that AMPK activation had
two distinct phases in primary erythroblasts. The phosphorylation of
AMPK (Thr172) and its target acetyl CoA carboxylase (Ser79) was ele-
vated in immature erythroblasts (glycophorin Alow), then decreased con-
jointly with erythroid differentiation. In erythroblasts, knockdown of
the a1 catalytic subunit by short hairpin RNA led to a decrease in cell
proliferation and alterations in the expression of membrane proteins
(band 3 and glycophorin A) associated with an increase in phosphoryla-
tion of adducin (Ser726). AMPK activation in mature erythroblasts (gly-
cophorin Ahigh), achieved through the use of direct activators (GSK621
and compound 991), induced cell cycle arrest in the S phase, the induc-
tion of autophagy and caspase-dependent apoptosis, whereas no such
effects were observed in similarly treated immature erythroblasts. Thus,
our work suggests that AMPK activation during the final stages of ery-
thropoiesis is deleterious. As the use of direct AMPK activators is being
considered as a treatment in several pathologies (diabetes, acute myeloid
leukemia), this observation is pivotal. Our data highlighted the impor-
tance of the finely-tuned regulation of AMPK during human erythro-
poiesis.
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ABSTRACT
Introduction 
Mammalian AMP-activated protein kinase (AMPK) is a highly conserved
eukaryotic serine/threonine protein kinase and a heterotrimeric complex consist-
ing of a single catalytic (a) and two regulatory (β and γ) subunits, encoded by dif-
ferent genes (a1, a2, β1, β2, γ1, γ2, and γ3). In the case of energy depletion, a
decrease in the cellular ATP-to-AMP ratio leads to allosteric AMPK activation by
AMP but also by the phosphorylation of Thr172 within the activation loop seg-
ment of the a subunit by an upstream AMPK kinase, liver kinase B1 (LKB1).
Another ‘‘canonical’’ mechanism of activation involves the phosphorylation of
Thr172 by calcium/calmodulin-dependent kinase kinase β (CaMKKβ) in response
to a rise in intracellular Ca2+.1 Once activated, AMPK phosphorylates metabolic
targets, leading to a decrease in ATP consumption and an increase in ATP produc-
tion. In particular, AMPK inhibits fatty acid synthesis via phosphorylation and
inactivation of acetyl-CoA-carboxylase (ACC) or induces autophagy via the phos-
phorylation of Unc-51 like autophagy activating kinase 1 (ULK1).2 Thus, AMPK is
a major sensor of energy status that maintains cellular
energy homeostasis but also exerts non-metabolic func-
tions such as the maintenance of cell survival, cell polarity
and regulation of the cell cycle.3,4
Erythropoiesis is a tightly regulated process that permits
the production of around two million red cells each second
throughout a human life, while the total cell number has to
be kept within a narrow margin. This extremely dynamic
process is also very flexible, since it must increase rapidly
in response to blood loss and hypoxia. Furthermore, main-
taining homeostasis is crucial and an imbalance in erythro-
poiesis can lead to the development of erythroid patholo-
gies such as polycythemias and anemia.
We and other groups have previously demonstrated
that AMPK plays a crucial role in the integrity and sur-
vival of red blood cells. We showed that mice that are
globally deficient in the catalytic subunit, Ampka1 but
not in those lacking the isoform Ampka2, as well as those
globally deficient in the regulatory subunits Ampkβ1 and
Ampkγ1, develop regenerative hemolytic anemia caused
by increased sequestration of abnormal erythrocytes.
Ampka1-/-, Ampkβ1-/- and Ampkγ1-/- mice develop
splenomegaly and iron accumulation due to a compensa-
tory response through extramedullary erythropoiesis in
the spleen and enhanced erythrophagocytosis. The life -
span of erythrocytes from Ampka1-/- and Ampkγ1-/- mice
was shorter than that of wild-type littermates. Moreover,
Ampka1-/- and Ampkγ1-/- erythrocytes were highly resist-
ant to osmotic stress and poorly deformable in response
to increasing shear stress, which is consistent with a loss
of membrane elasticity.5-8
The defects in Ampk-deficient erythrocytes suggested
that alterations might occur early during terminal ery-
throid maturation but no data were available on the
importance of AMPK in human erythropoiesis. We,
therefore, decided to investigate whether AMPK could be
implicated in regulating the proliferation, survival and dif-
ferentiation of human erythroid precursors. 
In the present study, we analyzed the expression and
activation of AMPK along human erythroid differentia-
tion. Our experiments show that AMPK is highly activat-
ed in immature erythroblasts and weakly active in mature
erythroblasts. We studied the impact of knocking down
AMPK and of AMPK activation by direct activators. In
erythroblasts, the knockdown of the AMPK α1 catalytic
subunit expression by short hairpin (sh) RNA induced a
decrease in cell proliferation and alterations in the expres-
sion or phosphorylation of membrane proteins whereas
no defect in hemoglobin synthesis or erythroid matura-
tion was observed. The activation of AMPK is necessary
in immature erythroblasts but maintaining the activation
in mature erythroblasts is deleterious, demonstrating that
AMPK activation has to be tightly regulated during
human terminal erythroid differentiation. 
Methods
Materials
AMPK a1 and a2 antibodies were obtained from Graham
Hardie (University of Dundee, UK);9,10 antibodies against the
AMPK β1 and γ1 isoforms, phospho-Thr 172 AMPK, phospho-
Ser 79 ACC, phospho-Ser 555 ULK1, LKB1, LC3B and cleaved
caspase 3 were from Cell Signaling Technology (Danvers, USA)
and anti-HSC70, anti-a spectrin, anti-band 3 and anti-P-Ser 726
adducin antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Actin (A5441) antibodies,
dexamethasone and chloroquine were purchased from Sigma-
Aldrich (Lyon, France). Anti-ankyrin antibodies were obtained
from Neuromab (Davis, CA, USA) (#75-380) and anti β-spectrin
antibodies from Abcam (Cambridge, UK). Compound GSK-621
was purchased from Selleckchem (Houston, TX, USA) and 991
(5-[[6-chloro-5-(1-methylindol-5-yl)-1H-benzimidazol-2-
yl]oxy]-2-methyl-benzoic acid) was synthesized by Spirochem
(Basel, Switzerland).
Cell lines and cell culture 
CD34+ cells were obtained from human donors who gave
informed consent in accordance with the Declaration of Helsinki
and the study was approved by the French ministry of higher
education and research review board. Granulocyte colony-stim-
ulating factor-mobilized CD34+ cells were purified from periph-
eral blood after cytapheresis. CD34+ cells were isolated by posi-
tive selection using an immunomagnetic procedure (MACS
CD34 isolation kit; Miltenyi Biotech (Paris, France). CD34+ cells
were cultured in 5% CO2 at 37°C for 7 days in IMDM medium
(Life Technologies, Waltham MA, USA) containing 1% gluta-
mine, 15% BIT 9500 (Stem Cell Technologies), 100 ng/mL stem
cell factor, 10 ng/mL interleukin-6 and 10 ng/mL interleukin-3
(Miltenyi Biotech). After 7 days of culture, CD36+ cells corre-
sponding to a highly purified population of human erythroid
progenitors were obtained by positive selection on CD36
immunomagnetic beads (CD36 unlabeled antibodies purchased
from Beckman Coulter, Villepinte, France) coupled to anti-
mouse IgG1 microbeads purchased from Miltenyi Biotech) .
CD36+ cells were then cultured with 2 U/mL erythropoietin, 100
ng/mL stem cell factor and 10 ng/mL interleukin-3 for up to 14
days for erythroid differentiation. GSK621 or compound 991
was added from day 0 after CD36+ selection; cells were counted
daily and diluted to a final concentration of 0.8 x106 cells/mL by
the addition of fresh medium containing the indicated concen-
tration of AMPK activator. Because of interindividual variability,
the kinetics of erythroid differentiation varies between different
human samples. Thus, the days of culture corresponding to the
same stage of differentiation have been grouped.
Lentiviral constructs, lentiviral production 
and cell infection
Lentiviral constructs for control and AMPKa1 shRNA
[(SHC002 and SHCLNG-NM006251 (TRCN00000000859),
respectively)] were purchased from Sigma (Lyon, France). To
obtain recombinant lentiviruses, 293T cells were transiently
transfected by calcium phosphate precipitation with three differ-
ent plasmids: pCMV-G (VSVG envelope coding sequence),
pCMV-gag-pol and a recombinant pLKO.1 vector encoding
either a control or AMPKa1 shRNA. Supernatants containing
infectious lentiviral particles were concentrated by ultracentrifu-
gation. Infections of human erythroblasts were performed at
day 1 and at day 4 after CD36 cell sorting and culture in the pres-
ence of interleukin-3, stem cell factor and erythropoietin, as
described above. 
Flow cytometry
Cells were labeled as previously described.11 Briefly, PC7-con-
jugated anti-glycophorin A (GPA), APC-conjugated anti-cd49d
(α4 integrin) or an appropriate isotype control were purchased
from Beckman Coulter; anti-BRIC6 (anti-band 3) was from the
NHSBT International Blood Group Reference Laboratory
(Bristol, UK). FITC-conjugated annexin V was used to measure
the percentage of cell apoptosis. 
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Cell proliferation
Cell proliferation was determined by trypan blue exclusion
dye.
Statistics
Results are expressed as means ± standard deviation (SD). A
Student t test was used to determine statistical significance. P val-
ues <0.05 were considered statistically significant.
Results 
AMPK a1 activation is tightly regulated during human
erythroid differentiation 
Because AMPK occurs as a heterotrimeric complex con-
taining catalytic a subunits and regulatory β and γ subunits,
we aimed to identify which isoforms are expressed in
human erythroblasts and to study their variation during
human erythroid differentiation. Human primary erythroid
progenitors were maintained for up to 12 days in culture
and were able to differentiate from the pro-erythroblastic
stage (day 2) to the reticulocyte stage (day 12) (Figure 1A
and Online Supplementary Figure S1 for cell morphology).
During maturation, erythroblasts progressively acquired
cell surface-specific markers such as GPA (from the pro-ery-
throblastic stage), band 3 (from the basophilic-erythroblas-
tic stage) and decreased expression of a4 integrin at the
orthochromatic erythroblast stage. They also started to syn-
thesize hemoglobin from the basophilic stage. Western blot
analysis demonstrated that the a1 catalytic subunit was
expressed while the a2 isoform was not detectable and that
the expression of a1 was constant along erythroid differen-
tiation (Figure 1B). The regulatory subunits, β1 and γ1, were
expressed throughout erythroid differentiation. We previ-
ously determined the copy number of individual proteins
for each stage of erythroid differentiation by an absolute
quantitative proteomics analysis.11 We confirmed the
expression of a1, β1 and γ1, while a2, β2 and γ2 isoforms
were not detectable by mass spectrometry analysis (Online
Supplementary Figure S2). Overall, our results suggest that
a1/β1/γ1 is the heterotrimeric complex that is predomi-
nantly present in human erythroblasts. 
Despite the global constant expression of AMPK, the acti-
vation of this protein might be modulated during differen-
tiation. We, therefore, studied AMPK activation by detec-
tion of phosphorylation of the a1 catalytic subunit at
Thr172 and phosphorylation of one of its substrates, ACC,
at Ser79 (Figure 1C). From day 2 to day 6, the phosphoryla-
tion of AMPK and ACC was clearly detectable, but con-
comitantly decreased from day 8 to the end of differentia-
tion. LKB1 was expressed throughout erythroid differentia-
tion. These data showed the biphasic pattern of activation
of AMPK during erythroid differentiation with clear activa-
tion in immature erythroblasts from the pro-erythroblast
stage until day 6 when the cells were GPAmed/band 3low
(basophilic erythroblasts) and reduced activation in mature
GPAhigh/band 3med erythroblasts from day 8 to day 12, corre-
sponding to stages from polychromatic erythroblasts to
reticulocytes.
The absence of AMPK induces decreased proliferation
and alterations  in the expression of membrane proteins
of human erythroblasts
To decipher the role of AMPK in erythroblasts, we inhib-
ited AMPK expression by a specific shRNA targeting the a1
catalytic subunit. Cells were infected by a lentivirus coding
for either shAMPKa1 or shControl (shCtrl) at day 1 and
then at day 4 after CD36 cell sorting. The decrease in a1
AMPK expression resulted in an expected decrease of the
phosphorylation of AMPK and its substrates ACC and
ULK1 (Figure 2A). No compensatory expression of the a2
catalytic subunit was observed in response to inhibition of
the a1 isoform (Online Supplementary Figure S3). The inhibi-
tion of AMPK a1 expression did not significantly modify
the differentiation of the cells. Indeed at days 6, 8 and 10 of
culture, the cell population was mainly composed of
basophilic erythroblasts, polychromatic erythroblasts and
orthochromatic erythroblasts, respectively, and this pattern
was not different when AMPKa1 was knocked down
(Figure 2B). The morphology of the shCtrl and shAMPKa1
cells was very similar (Online Supplementary Figure S4). The
percentages of hemoglobinized cells estimated at the indi-
cated stages of differentiation were identical between the
shCtrl and shAMPKa1 cells (Figure 2C). shAMPKa1 ery-
throblasts showed a reduced ability to proliferate compared
to shCtrl erythroblasts (Figure 2D). The inhibition of
AMPKa1 expression did not significantly affect the viability
of the cells measured by the trypan blue exclusion assay
(Figure 2E) or by annexin V flow cytometry analysis (data
not shown).
Because red cells from Ampka1-/- and Ampkγ1-/- mice are
highly resistant to osmotic stress and poorly deformable,
the expression of membrane proteins involved in these
processes was studied (Figure 3A). In shAMPKa1 polychro-
matic and orthochromatic erythroblasts, western blot
experiments showed that the phosphorylation of adducin
on Ser726 was increased while the expression of spectrins
and ankyrin was not affected (Figure 3A). Western blots
demonstrated that the global expression of band 3 was sig-
nificantly decreased in the shAMPKa1 cells while its
expression at the cell surface, measured by FACS, was
abnormally increased (Figure 3B). FACS analyses also
showed a decrease of the cell surface expression of GPA at
each stage of differentiation for the shAMPKa1 cells in
comparison to ShCtrl (39.9% at day 6/basophilic erythrob-
lasts, 50% at day 8/polychromatlic erythroblasts and
58.8% at day 10/orthochromatic erythroblast versus 100%
for shCtrl) (Figure 3C). Overall, the decrease in AMPK
expression induced major abnormalities in the expression
of the membrane proteins band 3 and GPA and, as in
murine Ampk knockout mice, led to enhanced phosphory-
lation of adducin. Furthermore, AMPKα1 knockdown pro-
voked a decrease in cell proliferation without affecting cell
viability and erythroblast maturation. 
Proliferation and survival of mature GPAhigh
erythroblasts are specifically and drastically 
diminished by GSK621-mediated AMPK activation 
To further investigate the role of AMPK in erythroid cells,
the activation of AMPK was enhanced by GSK621, a direct,
potent, novel activator of AMPK.12-15 In primary erythro -
blasts, the activation of AMPK by GSK621 was dose-depen-
dent, with increased phosphorylation of T172 AMPKa, and
also gradual stimulation of the phosphorylation of the sub-
strates of AMPK, ACC at Ser79 and ULK1 at Ser 555, from
5 to 20 mM (Figure 4A). The latter dose was then used in the
experiments. GSK621 was added to the medium from day
0 after CD36 cell sorting until the indicated days. GSK621
induced the phosphorylation of AMPK and its substrates at
each stage of erythroid maturation (Online Supplementary
Role of AMPK in human erythropoiesis
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Figure 1. Expression of AMPK isoforms and AMPK activation along terminal erythroid differentiation. (A) Representative experiment of one ex vivo culture of ery-
throblasts derived from CD34+ cells. Cells were analyzed on days 2, 4, 6, 8, 10 and 12 after CD36+ selection. Expression of cell surface markers GPA, band 3 and
a4β1 integrin was studied by flow cytometry along terminal erythroid differentiation. The percentage of hemoglobinized cells was determined by benzidine staining.
A minimum of 200 cells were counted and the percentage of blue-stained cells among the total cell count was determined. Cell morphology was examined following
staining with May-Grünwald-Giemsa; the percentage of each cell population was determined. (B) AMPK isoforms during erythropoiesis were determined by western
blot. Protein extracts from human primary erythroblasts from day 2 to day 12 of culture were analyzed by western blot using anti-a1, -a2, -β1, and -γ1 antibodies.
Anti-β-actin was used as a loading control and mouse liver protein extracts were used as a positive control for the expression of AMPKa2 (Ctrl). The a1, a2, and γ1
isoforms were analyzed on the same blot, the β1 isoform on a different one. (C) AMPK activation during erythroid differentiation. Anti-pT172 AMPK, anti-p S79 ACC,
anti AMPKa1 and LKB1 were used. Anti-β-actin or anti-HSC70 antibodies were used as loading controls. The upper panel shows a representative experiment of three
independent ones. Quantification of western blots and determination of the ratio between pAMPK/AMPK, pACC/AMPK and LKB1/AMPKa1 at the indicated days are
presented as the mean of three independent experiments ± SD;  ns: non-significant, *P<0.05 (lower panel). d: day; GPA: glycophorin A; AMPK: AMP-activated protein
kinase; ACC: acetyl-CoA-carboxylase; LKB1: liver kinase B1; HSC70: heat shock 70kDa protein; E: erythroblasts. 
A
B C
Role of AMPK in human erythropoiesis
haematologica | 2019; 104(5) 911
Figure 2. AMPKa1 knockdown reduces erythroblast proliferation without affecting erythroblast maturation. (A) Efficiency of AMPKa1 knockdown: Erythroblasts
were infected twice, on days 1 and 4 after CD36 cell sorting, with either a lentivirus coding a scrambled shRNA (sh Ctrl) or an AMPKa1 shRNA (shAMPK a1). The
efficiency of AMPKa1 knockdown in human primary erythroblasts was determined by anti-a1 AMPK, anti-PT172 AMPK, anti-PS79 ACC and anti-PS555 ULK1 western
blots on day 8 or day 10 with the same results. A representative experiment on day 8 is presented. Western blot quantification was performed with anti-β−actin or
anti-HSC70 antibodies; values are the mean of three independent experiments ± SD; ns: non-significant, *P<0.05. (B)  Effect of shAMPKa1 on erythroid cell matu-
ration. Cell composition for each culture at days 6, 8 and 10. The mean composition ± SD was calculated based on erythroblast morphology determined by May-
Grünwald-Giemsa staining in three independent experiments. (C) Absence of AMPKa1 does not modify the percentage of hemoglobinized cells. The percentage of
hemoglobinized cells was determined by benzidine staining at the indicated days of culture and corresponding stage of differentiation determined as in Figure 2A.
(D) Proliferation of shCtrl versus shAMPKa1 erythroblasts. Cumulative cell number was determined by counting cells with the trypan blue exclusion method at day
6 (basophilic erythroblasts), day 8 (polychromatic erythroblasts) and day 10 (orthochromatic erythroblasts) of culture. Results are expressed as the mean ± SD of
three independent experiments; ns: non-significant, *P<0.05. (E) Cell death in shAMPKa1 versus shCtrl cells. The proportion of dead cells was determined by trypan
blue exclusion dye at days 6, 8 and 10 of culture. Results are expressed as the mean ± SD of three independent experiments; ns: non-significant, *P<0.05. d: day;
GPA: glycophorin A; AMPK: AMP-activated protein kinase; ACC: acetyl-CoA-carboxylase; ULK1: Unc-51 like autophagy activating kinase 1; HSC70: heat shock 70kDa
protein; Pro-E: pro-erythroblasts; Baso-E: basophilic erythroblasts; Poly-E: polychromatic erythroblasts; Ortho-E: orthochromatic erythroblasts.
B C
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Figure 3. AMPK a1 knockdown disturbs glycophorin A, band 3 expression and phosphorylation of aduccin. (A) Analysis of expression of membrane proteins. Protein
extracts from human primary erythroblasts were analyzed by western blot using anti-AMPKa1 antibodies to confirm the knockdown and anti-spectrin a and β,
ankyrin, band 3, p-aduccin S726 antibodies. Anti-HSC70 was used as a loading control. AMPKa1, anti-spectrin a, ankyrin, band 3, p-adducin S726 were analyzed
on the same western blot, spectrin β on a distinct one (representative western blot at day 8/polychromatic erythroblasts, left panel), the same result was obtained
at day 10/polychromatic erythroblasts. The blots were quantified using anti-HSC70 antibodies; values are the mean ± SD of three independent experiments at day
8 and day 10; ns: non-significant, *P<0.05; (right panel). (B) Representative cytometry profile for band 3/a4 integrin gated on GPA-positive cells (left panel) The per-
centages of band 3lowa4 integrinhigh and band 3meda4 integrinmed in the shCtrl and shAMPKa1 cell populations are plotted in histograms (right panel). Results are
expressed as the mean ± SD of three independent experiments; ns: non-significant, *P<0.05; **P<0.01. (C) Expression of GPA determined by FACS. Representative
cytometry profiles are shown for GPA at day 6/basophilic erythroblasts, at day 8/polychromatic erythroblasts and at day 10/orthochromatic erythroblasts. Control
isotype: unfilled black for shCtrl,  unfilled gray for shAMPKa1; GPA-labeled: filled black for shCtrl, filled gray for shAMPKa1) (left panel). The histogram shows the
mean percentage of the GPA  fluorescence intensity on the cell surface; 100% represents the fluorescence intensity for shCtrl cells (right panel). Results are
expressed as the mean ± SD of three independent experiments; ns: non-significant, *P<0.05; **P<0.01. AMPK: AMP-activated protein kinase; HSC70: heat shock
70kDa protein; d: day; B3: band 3; Baso-E: basophilic erythroblasts; Poly-E: polychromatic erythroblasts; Ortho-E: orthochromatic erythroblasts; GPA: glycophorin A.
A
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Figure 4. GSK621-mediated AMPK activation decreases the proliferation of
mature erythroblasts. (A) GSK621 dose-dependent activation of AMPK in ery-
throblasts. Western blot analysis of PT172 AMPKa1, PS79 ACC and PS555 ULK1
in primary erythroblasts incubated for 3 h with increasing doses of GSK621. Anti-
HSC70 was used as a loading control. (B) GSK621 induces massive cell death
from days 5-7. The percentage of dead cells was determined by trypan blue
exclusion dye. In the three experiments, the days of culture were grouped at the
same stage of differentiation for the vehicle-treated cells (see Methods section).
(C) Inhibition of erythroblast proliferation by GSK621. Erythroid cells were incu-
bated in the absence (vehicle) or presence of 20 mM GSK621 from day 0.
Cumulative cell number was determined by counting cells with the trypan blue
exclusion method at day 0, days 3-4, days 5-7 and days 8-9 in three independent
cultures. (D) GSK621 induces an accumulation of cells in the S phase. Erythroid
cells were incubated in the absence (vehicle) or presence of 20 mM GSK621
from day 0 to the indicated days. The propidium Iodide incorporation assay was
performed. A representative experiment is shown; four independent experiments
were performed and the results from day 9 are expressed as the mean ± SD; ns:
non-significant, *P<0.05. AMPK: AMP-activated protein kinase; ACC: acetyl-CoA-
carboxylase; ULK1: Unc-51 like autophagy activating kinase 1; HSC70: heat
shock 70kDa protein; d: day.
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Figure S5). GSK621 provoked 32% cell death at days 5-7
and 70% at days 8-9 (Figure 4B). GSK621 dramatically
reduced the proliferation of cells with a more drastic impact
on the most mature erythroblasts (Figure 4C). 
To gain further insight into the inhibition of mature ery-
throblast proliferation by GSK621, the cell cycle was ana-
lyzed by quantification of DNA content with propidium
iodide. At days 8 and 9, GSK921 induced a reduction in the
number of cells in the G2/M phase of the cell cycle and an
increase in cells in the early S phase, demonstrating block-
age in the S phase (Figure 4D). The protein level of AMPK
substrates involved in the cell cycle, P5316 and a target gene
of P53, P21 was determined. GSK621-mediated cell cycle
arrest was not due to the phosphorylation and consequent
stabilization of P53 since there was no variation in their
expression, which is in agreement with the absence of
defects in G1/S transition (Online Supplementary Figure S6).
We then studied in more detail whether GSK621-mediat-
ed AMPK activation could affect erythroblast differentia-
tion. In this set of experiments, at days 3-4 cells were imma-
ture and did not synthesize hemoglobin, while at days 8-9,
more than 80% of the cells were hemoglobinized (Figure
5A). In the presence of GSK621, at days 8-9, the percentage
of cells that synthesized hemoglobin was very low.
To decipher more precisely the stage at which the
GSK621-mediated activation of AMPK induced cell death,
erythroblasts were analyzed for GPA and annexin V by
flow cytometry (Figure 5B). GSK621 did not affect imma-
ture GPAlow cells at days 3-4, but induced massive death of
GPAhigh erythroblasts at days 5-7 (46% annexin V-positive
cells with GSK621 versus 16% in control cells) and at days
8-9 (75% versus 16%, respectively). Indeed, after AMPK
activation at days 5-7, only 3.5% of erythroblasts were
GPAhigh, in contrast to 46.4% in control cells. Furthermore,
at day 7 only 7.5% of GSK621-treated cells were band 3high
compared to 42% of control cells. At day 9, in the control
conditions, erythroid cells continued to differentiate, which
is in contrast to immature GSK621-treated cells.
Furthermore, morphological studies after staining with
May-Grünwald-Giemsa confirmed the blockage in matura-
tion. Indeed, in vehicle-treated cultures, at day 9, the popu-
lation was mainly constituted of polychromatic erythro -
blasts, and at day 14, orthochromatic erythroblasts and
reticulocytes, whereas in the GSK621-treated culture, at
days 9 and 14, cells were very immature with large nuclei
and uncondensed chromatin; no mature cells were detected
at day 14 (Figure 5C). The same results (decreased prolifer-
ation and survival, differentiation blockage) were obtained
with another direct activator, compound 991 (Online
Supplementary Figure S7). Overall, our results show that acti-
vation of AMPK by direct activators induced a blockage in
the cell cycle, proliferation arrest and death of mature ery-
throblasts after the basophilic stage.
To reinforce our data, we took advantage of the fact that
erythroid progenitors and early precursors can proliferate
with delayed differentiation in response to erythropoietin,
stem cell factor and dexamethasone.17 We maintained the
cells for the indicated number of days in culture medium
with vehicle, GSK621, dexamethasone + vehicle or dexam-
ethasone + GSK621 (Figure 6A). As expected, the presence
of dexamethasone delayed erythroid differentiation, as
demonstrated by the absence of a GPAhigh population after 7
days and even 9 days of culture. After 7 days, GSK621
induced cell death, as previously described (Figures 4B and
5B), with 54.6% of cells being positive for annexin V and
35.3% being stained by trypan blue; however, immature
erythroblasts treated with dexamethasone + GSK621 were
resistant to GSK621-induced cell death. Indeed, only 23.4%
of cells were annexin V-positive and 16.6% were stained by
trypan blue (Figure 6A,B).
To confirm that the activation of AMPK in mature ery-
throblasts provoked cell death, GSK621 was added for 24
and 48 h on day 9 when the erythroblastic population
already contained 35% of mature GPAhigh cells (Figure 6C).
The GPA/annexin V staining clearly demonstrated that
GSK621 induced massive death in mature GPAhigh cells
within less than 48 h. With GSK621, 52% of the total cells
were positive for annexin V and 43% were stained by try-
pan blue versus 16% and 10%, respectively, of the control
cells. 
Overall, our results demonstrated that the activation of
AMPK was deleterious for mature GPAhigh cells, specifically
in contrast to immature erythroblasts (from the progenitor
stage to the basophilic stage), which were not affected.
AMPK activation induced autophagy and apoptotic death
of mature erythroblasts
In erythroblasts, AMPK activation leads to ULK1 phos-
phorylation at S555 (Figure 4A), which is well known to be
important for the induction of autophagy in several types of
cells.18 In GSK621-treated erythroblasts, LC3B-II accumula-
tion was clearly detected by immunoblotting (Figure 7A,
left panel). The induction of autophagy was confirmed by
the use of chloroquine, which blocks the degradation of
autophagosomes.19 Indeed, in addition to GSK621, chloro-
quine treatment further increased LC3B-II, showing that
the activation of AMPK by GSK621 in mature erythroblasts
induced autophagy (Figure 7A, right panel). 
We, therefore, wondered whether GSK621 provoked cas-
pase-dependent apoptotic cell death and treated cells with
a pan-caspase inhibitor Q-VD-OPh (QVD) in addition to
GSK621. When caspase activity was blocked by QVD for
48 h (as demonstrated by the anti-cleaved-caspase 3
immunoblot), mature erythroblasts were protected from
GSK621-induced cell death, showing that AMPK activation
induced caspase-dependent apoptotic cell death (Figure 7B). 
Discussion 
Ampk a1-/-, Ampk β1-/- and Ampk γ1-/- mice develop
hemolytic anemia, and the plasma membrane of their red
blood cells shows elasticity defects.5–8 The membrane com-
position evolves continuously throughout erythropoiesis
and during red blood cell maturation; the defects due to the
absence of Ampk are most likely initiated during erythro-
poiesis. We, therefore, studied the role of AMPK during
human erythropoiesis. 
As in murine red blood cells,5 a1 is the only catalytic sub-
unit expressed in erythroblasts, a2 is not detected and we
showed that the heterotrimer a1/β1/γ1 is predominant
from erythroid progenitors to orthochromatic erythro -
blasts.
During the earliest stages of terminal differentiation, from
progenitors to the basophilic stage, AMPK is activated and
then its activation is drastically reduced to the reticulocyte
stage. Several kinases and phosphatases regulate AMPK
activation.1,20 AMPK is activated by phosphorylation at
T172 by three upstream kinases: LKB1, which seems to be
constitutively active, CaMKK2 which is activated by an
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Figure 5. GSK621-mediated AMPK activation specifically and drastically decreases the survival of mature GPAhigh erythroblasts. (A) GSK621-dependent AMPK acti-
vation reduces the percentage of hemoglobinized cells. The percentage of hemoglobinized cells was determined by benzidine staining after incubation in the absence
(vehicle) or presence of 20 mM GSK621 from day 0 to the indicated days. (B) GSK621-mediated AMPK activation blocked erythroblast differentiation. Erythroblasts
were incubated in the absence (vehicle) or presence of 20 mM GSK621 from day 0 to the indicated days. Representative cytometry profiles for GPA/annexin V and
band 3/a4 integrin are shown. For the GPA/annexin V profiles, annexin V-positive cells are shown in the upper part of the quadrant and GPAhigh cells in the right part.
The percentage of GPAhigh cells and percentage of annexin V-positive cells are represented. Results are expressed as the mean ± SD of three independent experi-
ments; ns: non-significant, *P<0.05. (C) Morphology was analyzed by May-Grünwald-Giemsa staining. Representative experiments at day 4, day 9 and day 14 are
shown. d: day; GPA: glycophorin A.
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Figure 6. AMPK activation by GSK621 provokes the death of mature GPAhigh erythroblasts. (A) GSK621 does not increase the percentage of annexin V-positive cells
in an immature cell population. Erythroid cells were incubated in the absence (vehicle) or presence of 20 mM GSK621 and 2x10-7 M dexamethasone (Dexa)/vehicle
or Dexa/GSK621 from day 0 to the indicated days. Cells were labeled with anti-GPA antibodies and annexin V before analysis by flow cytometry. A representative
experiment and the percentage of annexin V-positive cells from three experiments are shown. (B) GSK621 does not induce cell death when the population of ery-
throblasts is immature. The proportion of dead cells was determined by trypan blue exclusion dye assay. (C) GSK621-mediated AMPK activation specifically induces
the death of mature day 9 erythroblasts. Mature erythroblasts were incubated in the absence (vehicle) or presence of 20 mM GSK621 for 24 or 48 h. Cells were incu-
bated with anti-GPA antibodies and annexin V before analysis by flow cytometry. A representative experiment and the percentage of annexin V-positive cells from
three experiments are shown (lower panel). (D) The proportion of dead cells was determined by a trypan blue exclusion dye assay. Results are expressed as the mean
± SD. *P<0.05, **P<0.01, ***P<0.001. d: day; Dexa: dexamethasone; GPA: glycophorin A; h: hours.
increase in cytosolic Ca2+, and possibly TAK1, which is acti-
vated by cytokines. The phosphatases PP1, PP2A and PP2C
dephosphorylate T172 and the kinases GSK3, PKA, PKB,
and PKC inhibit AMPK activation; they may contribute to
the reduced AMPK activation in mature erythroblasts. Our
data from the quantitative mass spectrometry analysis of
human erythropoiesis11 did not allow us to quantify these
kinases and phosphatases because of their absence, their
very weak expression or the scarcity of peptides generated.
Nevertheless, our western blot studies showed the expres-
sion of LKB1 along erythroid differentiation and suggested
that LKB1 could be the upstream activating kinase for
AMPKa1. Further studies are needed to understand the
kinetics of AMPK activation and its upstream regulators
during erythroid terminal differentiation. 
Our results in human erythroblasts show that knock-
down of the expression of the a1 subunit by shRNA
induces a decrease in cell proliferation and does not inhibit
cell survival or erythroid maturation. Red blood cells from
Ampk a1-/-mice have defects in membrane elasticity leading
to hemolytic anemia. The absence of the a1 subunit in
human erythroblasts induces important changes in the
expression of membrane proteins and could potentially
affect the expression of membrane proteins involved later
in erythrocyte membrane elasticity. As we previously
showed, phosphorylation of adducin at Ser724 is increased
in red blood cells from Ampk a1-/- and Ampk γ1-/- mice. Our
data demonstrate that this modification is also present ear-
lier in human erythroblasts. Interestingly, in sickle cell dis-
ease, the reduction of red blood cell deformability is associ-
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Figure 7. GSK621-mediated AMPK activation leads to autophagy and apoptosis. (A) GSK621-mediated AMPK activation induces autophagy. Erythroid cells were
incubated in the absence (vehicle) or presence of 20 mM GSK621 from day 0 to the indicated days of culture (left panel). Chloroquine (10 mM) was added for 4 h
before harvesting the cells (right panel). LC3BII was detected by western blot experiments using specific antibodies. Anti-β actin or anti-HSC70 antibodies were used
as loading controls. (B) GSK621 provokes the caspase-dependent apoptosis of mature day 8 erythroblasts. Mature erythroblasts were incubated in the absence
(vehicle) or presence of 20 mM GSK621 or 20 µM GSK621 and 10 mM QVD for 48 h; cells were labeled with anti-GPA and for annexin V binding and analyzed by flow
cytometry. A representative experiment and the percentage of annexin V-positive cells from three experiments are shown. Results are expressed as the mean ± SD.
*P<0.05, **P<0.01. Efficiency of QVD to block caspase activity was determined by western blot using an anti-caspase 3 antibody that specifically detects the cleaved
isoform of caspase 3. β-actin was used as a loading control. d: day; CQ: chloroquine; GPA: glycophorin A; QVD: Q-VD-OPh. 
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ated with increased phosphorylation of adducin at Ser
726.21 Thus, it would be interesting to determine whether
AMPK plays a role in this pathology. Our results suggest
that expression of band 3 is regulated by AMPKa1.
Through in vitro studies, Thali et al. identified band 3 as a
potential direct substrate for AMPK.22 An attractive hypoth-
esis would be that AMPK induces band 3 phosphorylation
resulting in an increase in its global expression but a less
efficient expression at the cell surface of erythroblasts.  
To activate AMPK specifically, we used direct activators
of AMPK because these molecules bind directly to the β
subunit and do not affect the AMP/ATP ratio as metformin
does. Several recent studies have demonstrated the involve-
ment and specificity of GSK621 in activating AMPK.12-15 In
hematopoietic cells, GSK621 has been reported to be more
potent in primary acute myeloid leukemia cells and cell
lines than the direct activator A-769662.12
In the present study, we demonstrated, through the use
of direct activators (GSK621 and compound 991), that
AMPK activation in mature erythroblasts (GPAhigh) (poly-
chromatic to reticulocytes) induced apoptotic cell death,
whereas no such effect was observed in similarly treated
immature erythroblasts. Furthermore, the fact that
GSK621 induced the apoptosis of mature erythroblasts
after only 48 h of treatment but did not affect erythrob-
lasts that were maintained in an immature state (by dex-
amethasone) after 9 days of GSK621 excludes a potential
toxic effect due to the accumulation of compounds. We
propose that maintaining AMPK activation after the
basophilic stage, when AMPK is not normally activated,
induces cell cycle arrest followed by the induction of
autophagy and caspase-dependent apoptosis. Thus, our
work suggests that AMPK activation during the final
stages of erythropoiesis is deleterious.
The present work highlights the role of AMPK in erythro-
poiesis and adds further support to the involvement of
AMPK in the regulation of hematopoiesis. In hematopoietic
stem cells, AMPK deficiency partially phenocopies the
mitochondrial defects observed in Lkb1-/- mice without
affecting hematopoietic stem cell maintenance,23 Obba et al.
recently demonstrated that the activation of AMPK is cru-
cial for CSF-1-induced autophagy and human monocyte
differentiation into macrophages.24 Our results demonstrate
the importance of the finely tuned regulation of AMPK dur-
ing adult human erythropoiesis. This observation is of sig-
nificant value since deciphering the molecular mechanisms
regulating proliferation, survival and differentiation of ery-
throblasts is necessary to better understand how erythroid
progenitors and precursors can physiologically give rise to
red blood cells. The use of direct AMPK activators is being
considered as a therapeutic treatment in several chronic
metabolic diseases. Phase I and II trials investigating the use
of the activators PXL770 (clinical trial NCT03395470) and
compound 0304 (betagenon.se) are in progress in patients
with non-alcoholic hepatic steatosis or type 2 diabetes.
These activators could induce the apoptosis of mature ery-
throblasts in the bone marrow so it will be necessary to
analyze hematologic parameters to prevent potential ane-
mia.
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